New Evidence On Easing Inflammation Of Brain Cells For Alzheimer's Disease
Wenhui Hu and colleagues point out that existing drugs for AD provide only "minimal" relief of memory loss and other symptoms, creating an urgent need for new medicines that actually combat the underlying destruction of brain cells. Research suggests that inflammation of nerve cells in the brain is a key part of that process. One medicine, Minozac, is in clinical trials. But Hu says Minozac still has more space to improve its efficacy. So the scientists sifted through compounds with a molecular architecture similar to Minozac in an effort to find more active substances.
The report describes success in doing so. They discovered one compound that appeared especially effective in relieving nerve inflammation and in improving learning and memory in lab mice widely used in AD research. "In general, this study not only proves that countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's disease, but also provides a good lead compound with efficacy comparable to donepezil [an existing AD medicine] for further oral anti-AD drug discovery and development," the report states.
“Identification of Aminopyridazine-Derived Anti-neuroinflammatory Agents Effective in An Alzheimer’s Mouse Model”
American Chemical Society - Medicinal Chemistry Letters
Please use one of the following formats to cite this article in your essay, paper or report:
American Chemical Society. "New Evidence On Easing Inflammation Of Brain Cells For Alzheimer's Disease." Medical News Today. MediLexicon, Intl., 5 Oct. 2012. Web.
9 Feb. 2016. <http://www.medicalnewstoday.com/releases/251124.php>
American Chemical Society. (2012, October 5). "New Evidence On Easing Inflammation Of Brain Cells For Alzheimer's Disease." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.